Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H3Cl3O2 |
Molecular Weight | 165.403 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(O)C(Cl)(Cl)Cl
InChI
InChIKey=RNFNDJAIBTYOQL-UHFFFAOYSA-N
InChI=1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H
Molecular Formula | C2H3Cl3O2 |
Molecular Weight | 165.403 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CHLORAL BETAINE, a chemical complex of chloral hydrate and betaine, is a nonbarbiturate sedative and hypnotic. It is indicated for sleep induction, preoperative sedation, and daytime sedation. CHLORAL BETAINE is converted to chloral hydrate in the body and its action on the central nervous system is identical with that of chloral hydrate.
CNS Activity
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Beta-Chlor Approved UseCloral Betaine Tablets are used for the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed. Cloral Betaine Tablets should be used as an adjunct to non-pharmacological therapies. Launch Date1962 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
106 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18243465/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
2,2,2-TRICHLOROETHANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1056 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18243465/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
2,2,2-TRICHLOROETHANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18243465/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
2,2,2-TRICHLOROETHANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
88 mg/kg single, intravenous Overdose Dose: 88 mg/kg Route: intravenous Route: single Dose: 88 mg/kg Sources: Page: p.102 |
healthy, 1.25 n = 1 Health Status: healthy Age Group: 1.25 Sex: M Population Size: 1 Sources: Page: p.102 |
Disc. AE: Cyanosis, Lethargy... AEs leading to discontinuation/dose reduction: Cyanosis Sources: Page: p.102Lethargy |
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.246 |
healthy, 27 n = 1 Health Status: healthy Age Group: 27 Sex: M Population Size: 1 Sources: Page: p.246 |
Disc. AE: Hypotension, Ventricular tachycardia... AEs leading to discontinuation/dose reduction: Hypotension Sources: Page: p.246Ventricular tachycardia |
39 mg/kg single, intravenous Overdose Dose: 39 mg/kg Route: intravenous Route: single Dose: 39 mg/kg Sources: Page: p.102 |
healthy, 3 n = 1 Health Status: healthy Age Group: 3 Sex: F Population Size: 1 Sources: Page: p.102 |
Disc. AE: Lethargy... AEs leading to discontinuation/dose reduction: Lethargy Sources: Page: p.102 |
38 g single, oral Overdose Dose: 38 g Route: oral Route: single Dose: 38 g Sources: Page: p.136 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Depression Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.136 |
Disc. AE: Cyanosis, Coma... AEs leading to discontinuation/dose reduction: Cyanosis Sources: Page: p.136Coma Hypotension Ventricular tachycardia |
30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: Page: p.246 |
healthy, 39 n = 1 Health Status: healthy Age Group: 39 Sex: F Population Size: 1 Sources: Page: p.246 |
Disc. AE: Supraventricular tachycardia, Premature ventricular contractions... AEs leading to discontinuation/dose reduction: Supraventricular tachycardia Sources: Page: p.246Premature ventricular contractions |
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.246 |
healthy, 42 n = 1 Health Status: healthy Age Group: 42 Sex: F Population Size: 1 Sources: Page: p.246 |
Disc. AE: Chest pain, Tachycardia... AEs leading to discontinuation/dose reduction: Chest pain Sources: Page: p.246Tachycardia |
30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: Page: p.232 |
healthy, 67 n = 1 Health Status: healthy Age Group: 67 Sex: F Population Size: 1 Sources: Page: p.232 |
Disc. AE: Ventricular tachycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Sources: Page: p.232 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cyanosis | Disc. AE | 88 mg/kg single, intravenous Overdose Dose: 88 mg/kg Route: intravenous Route: single Dose: 88 mg/kg Sources: Page: p.102 |
healthy, 1.25 n = 1 Health Status: healthy Age Group: 1.25 Sex: M Population Size: 1 Sources: Page: p.102 |
Lethargy | Disc. AE | 88 mg/kg single, intravenous Overdose Dose: 88 mg/kg Route: intravenous Route: single Dose: 88 mg/kg Sources: Page: p.102 |
healthy, 1.25 n = 1 Health Status: healthy Age Group: 1.25 Sex: M Population Size: 1 Sources: Page: p.102 |
Hypotension | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.246 |
healthy, 27 n = 1 Health Status: healthy Age Group: 27 Sex: M Population Size: 1 Sources: Page: p.246 |
Ventricular tachycardia | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.246 |
healthy, 27 n = 1 Health Status: healthy Age Group: 27 Sex: M Population Size: 1 Sources: Page: p.246 |
Lethargy | Disc. AE | 39 mg/kg single, intravenous Overdose Dose: 39 mg/kg Route: intravenous Route: single Dose: 39 mg/kg Sources: Page: p.102 |
healthy, 3 n = 1 Health Status: healthy Age Group: 3 Sex: F Population Size: 1 Sources: Page: p.102 |
Coma | Disc. AE | 38 g single, oral Overdose Dose: 38 g Route: oral Route: single Dose: 38 g Sources: Page: p.136 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Depression Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.136 |
Cyanosis | Disc. AE | 38 g single, oral Overdose Dose: 38 g Route: oral Route: single Dose: 38 g Sources: Page: p.136 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Depression Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.136 |
Hypotension | Disc. AE | 38 g single, oral Overdose Dose: 38 g Route: oral Route: single Dose: 38 g Sources: Page: p.136 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Depression Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.136 |
Ventricular tachycardia | Disc. AE | 38 g single, oral Overdose Dose: 38 g Route: oral Route: single Dose: 38 g Sources: Page: p.136 |
unhealthy, 38 n = 1 Health Status: unhealthy Condition: Depression Age Group: 38 Sex: F Population Size: 1 Sources: Page: p.136 |
Premature ventricular contractions | Disc. AE | 30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: Page: p.246 |
healthy, 39 n = 1 Health Status: healthy Age Group: 39 Sex: F Population Size: 1 Sources: Page: p.246 |
Supraventricular tachycardia | Disc. AE | 30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: Page: p.246 |
healthy, 39 n = 1 Health Status: healthy Age Group: 39 Sex: F Population Size: 1 Sources: Page: p.246 |
Chest pain | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.246 |
healthy, 42 n = 1 Health Status: healthy Age Group: 42 Sex: F Population Size: 1 Sources: Page: p.246 |
Tachycardia | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.246 |
healthy, 42 n = 1 Health Status: healthy Age Group: 42 Sex: F Population Size: 1 Sources: Page: p.246 |
Ventricular tachycardia | Disc. AE | 30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: Page: p.232 |
healthy, 67 n = 1 Health Status: healthy Age Group: 67 Sex: F Population Size: 1 Sources: Page: p.232 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/33/10/1429 Page: 1.0 |
major | |||
Sources: https://dmd.aspetjournals.org/content/33/10/1429 Page: 1.0 |
minor |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14212304
To induce sleep, the recommended dosage for adults and children over 12 years of age is 870 mg to 1.7 gm approximately 15 to 30 minutes before bedtime.
For preoperative sedation, the same amounts are given 60 to 90 minutes before surgery.
The suggested sedative dosage is 870 mg given three times daily, with an additional dose at bedtime if necessary.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:04:25 GMT 2023
by
admin
on
Fri Dec 15 15:04:25 GMT 2023
|
Record UNII |
418M5916WG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2465
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
WHO-VATC |
QN05CC01
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
CFR |
21 CFR 1308.22
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
LIVERTOX |
188
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
EPA PESTICIDE CODE |
268100
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
NCI_THESAURUS |
C2199
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
CFR |
21 CFR 522.380
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
||
|
WHO-ATC |
N05CC01
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
28142
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
3210
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
CHLORAL HYDRATE
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
Chloral Hydrate
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
m3341
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB01563
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
2707
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
C28922
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
302-17-0
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
222
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
CHLORAL HYDRATE
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | Description: Colourless, transparent or white crystals; odour, aromatic, pungent and characteristic. Solubility: Very soluble in water; freely soluble in ethanol (~750 g/l) TS and ether R. Category: Premedication. Storage: Chloral hydrate should be kept in a tightly closed container. Additional information: Melting temperature, about 55 ?C; when exposed to air it slowly volatilizes. Requirement: Chloral hydrate contains not less than 98.5% and not more than 101.0% of C2H3Cl3O2.Note: Prepare the following test solution for use in "Identity tests A and B", and for "Clarity and colour". Dissolve 2.5 g in sufficientcarbon-dioxide-free water R to produce 25 mL. | ||
|
D002697
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
418M5916WG
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
100000085010
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
SUB13324MIG
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
2344
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB13325MIG
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
ALTERNATIVE | |||
|
206-117-5
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
586
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
418M5916WG
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
DTXSID7020261
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL455917
Created by
admin on Fri Dec 15 15:04:25 GMT 2023 , Edited by admin on Fri Dec 15 15:04:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
Percent of dose excreted in urine as metabolite.
May be responsible for the hypnotic activity of the parent drug in man.
URINE
|
||
|
METABOLITE ACTIVE -> PRODRUG |
MAJOR
|